Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BIIB vs ILMN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BIIB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)
BIIB Overall Winner
6-Pillar Tally: BIIB 4 – 2 ILMN
Matrix Metrics: BIIB 6 – 4 ILMN
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Illumina Inc (ILMN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ILMN carries 55.1/100 (HOLD) at $200.12 (33.5x Forward P/E, 19.1% operating margin).
- Composite vs. Pillar Nuance: While ILMN currently prints a higher short-term Unified Composite Score (55.1/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 19.1% operating margin) and revenue trajectory (+10.6% vs. +4.2% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BIIB vs ILMN
BIIB
Head-to-Head Winner
Biogen Inc. Common Stock
$252.72
-0.27% 1D
Market Cap
$37.0B
TTM Revenue
$10.3B
Forward P/E
15.6x
Beta / 30D Vol
0.27β · 36% Vol
Unified Composite Score
50.2
HOLD
Tech 45.0
Fund 52.0
Flow 64.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
ILMN
Illumina Inc
$200.12
-3.33% 1D
Market Cap
$31.7B
TTM Revenue
$4.54B
Forward P/E
33.5x
Beta / 30D Vol
1.34β · 85% Vol
Unified Composite Score
55.1
HOLD
Tech 53.0
Fund 57.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (BIIB 4 – 2 ILMN)
1. Valuation Multiples
BIIB
Forward P/E
15.6x
33.5x
Trailing P/E
109.9x
36.6x
PEG Ratio
3.45x
2.62x
EV / Revenue
4.2x
7.2x
2. Growth & Scale
BIIB
Revenue Growth (YoY)
+10.6%
+4.2%
Earnings Growth (YoY)
-84.8%
+45.9%
TTM Revenue (USD)
$10.3B
$4.54B
Market Cap
$37.0B
$31.7B
3. Profitability & Quality
BIIB
Gross Margin
75.8%
67.7%
Operating Margin
23.5%
19.1%
Net Profit Margin
3.4%
19.7%
Return on Equity (ROE)
1.9%
32.4%
4. Balance Sheet & Cash Flow
ILMN
Cash Generation (TTM)
$1.64B
$1.14B EBITDA
Cash Flow Margin
16.0%
25.2% EBITDA Mgn
Net Cash / Leverage
$6.50B Net Debt (0.41x D/E)
$1.02B Net Debt (0.74x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BIIB
Options Structure Phase
CONSOLIDATION
CONSOLIDATION
Current IV / %ile
18.4% (6th %ile)
50.0% (24th %ile)
Put/Call OI Skew
0.77x (Call-Skewed)
0.68x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Markup
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
ILMN
OpEx & R&D Intensity
52.3% of Rev ($5.39B)
48.6% of Rev ($2.21B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Concentrated Oligopoly Moat
Supply-Chain Role
Drug Manufacturers - General Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BIIB (6) vs ILMN (4)| Institutional Metric | BIIB | ILMN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $37.0B | $31.7B | BIIB | |
| Trailing P/E Ratio | 109.9x | 36.6x | ILMN | |
| Forward P/E Ratio | 15.6x | 33.5x | BIIB | |
| Revenue Growth (YoY) | +10.6% | +4.2% | BIIB | |
| Operating Margin (TTM) | 23.5% | 19.1% | BIIB | |
| Net Profit Margin | 3.4% | 19.7% | ILMN | |
| Return on Equity (ROE) | 1.9% | 32.4% | ILMN | |
| 52-Week Range Position | 92% ($160–$261) | 44% ($113–$309) | BIIB | |
| Beta / 30D Volatility | 0.27β · 36% Vol | 1.34β · 85% Vol | BIIB | |
| Unified Institutional Score | 50.2 / 100 (HOLD) | 55.1 / 100 (HOLD) | ILMN | |
| Trailing 12M Revenue (USD) | $10.3B | $4.54B | Scale | |
| Gross Profit Margin (TTM) | 75.8% | 67.7% | Quality | |
| PEG Ratio & EV / Revenue | 3.45x PEG · 4.2x EV/Rev | 2.62x PEG · 7.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $1.64B ($6.50B Net Debt (0.41x D/E)) | $1.14B EBITDA ($1.02B Net Debt (0.74x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BIIB +32.41 pp
3M Horizon
BIIB +12.62 pp
6M Horizon
ILMN +9.73 pp
1Y Horizon
ILMN +13.45 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BIIB Revenue | ILMN Revenue | BIIB Op. Margin | ILMN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $13.4B | $3.33B | 43.8% | 26.5% | BIIB |
| FY2019 | $14.4B | $3.54B | 49.0% | 27.8% | BIIB |
| FY2020 | $13.4B | N/A | 33.8% | N/A | BIIB |
| FY2021 | $11.0B | $3.24B | 25.9% | 17.9% | BIIB |
| FY2022 | $10.2B | $4.53B | 29.9% | -2.7% | BIIB |
| FY2023 | $9.84B | $4.50B | 11.8% | -23.7% | BIIB |
| FY2024 | $9.68B | $4.37B | 16.9% | -19.1% | BIIB |
| FY2025 | $9.89B | $4.34B | 13.1% | 18.6% | ILMN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BIIB
CONSOLIDATION
Current IV
18.4%
IV Percentile
6th %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ILMN
CONSOLIDATION
Current IV
50.0%
IV Percentile
24th %ile
Put/Call OI Skew
0.68x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact ILMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BIIB Moat Profile
Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
OpEx & R&D Reinvestment
52.3% of Rev ($5.39B)
90D Engineering Disclosures
0 Published
ILMN Moat Profile
Concentrated Oligopoly Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
48.6% of Rev ($2.21B)
90D Engineering Disclosures
0 Published · Spatial Genomics
Investor FAQ BIIB vs ILMN Key Questions & Quantitative Answers
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Illumina Inc (ILMN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas ILMN carries 55.1/100 (HOLD) at $200.12 (33.5x Forward P/E, 19.1% operating margin). Composite vs. Pillar Nuance: While ILMN currently prints a higher short-term Unified Composite Score (55.1/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 19.1% operating margin) and revenue trajectory (+10.6% vs. +4.2% YoY).
BIIB leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with ILMN at +4.2% YoY revenue growth and +45.9% YoY earnings growth on $4.54B TTM revenue (67.7% gross margin, 19.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BIIB cumulative revenue shifted -26.5% while ILMN shifted +30.3%. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus 48.6% of Rev ($2.21B) (0 disclosures) for ILMN.
BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas ILMN trades at 33.5x Forward P/E, 36.6x Trailing P/E, 2.62x PEG, and 7.2x EV/Revenue (25.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus ILMN (32.4% ROE) capital efficiency.
In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, ILMN carries 50.0% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.68x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.34β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ILMN vs BIIB · Reverse Pair
BIIB vs REGN
· Sector Peer
BIIB vs AMGN
· Sector Peer
BIIB vs GILD
· Sector Peer
ILMN vs REGN
· Sector Peer
ILMN vs VRTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem